Involved pharmaceutical companies in the Thrombotic Thrombocytopenic Purpura market are Takeda, Lee’s Pharmaceutical and others.
DelveInsight’s Thrombotic Thrombocytopenic Purpura Pipeline Report provides a disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. This report gives a detailed clinical and non-clinical stage products analysis. The TTP report also highlights the unmet needs with respect to the development of Thrombotic Thrombocytopenic Purpura.
Some of the key highlights from the Thrombotic Thrombocytopenic Purpura Pipeline Report-
- Apadamtase alfa: TAK-755 is the first and only ADAMTS13 replacement therapy currently in development for both types of TTP. TAK-755 can possibly be a groundbreaking treatment for thrombotic thrombocytopenic purpura, an uncommon and perilous thickening issue characterized by low or missing circling ADAMTS13 action.
- The Apadamtase alfa (Takeda) drug has received an orphan designation for Thrombotic Thrombocytopenic Purpura from the US FDA.
- Key companies involved in the Thrombotic Thrombocytopenic Purpura Pipeline are Takeda, Lee’s Pharmaceutical
Request for Sample @ Thrombotic Thrombocytopenic Purpura Pipeline Insight
Thrombotic Thrombocytopenic Purpura (TTP) is a rare, life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anaemia, severe thrombocytopenia, and organ ischemia with profound thrombocytopenia. TTP is characterized by a severe deficiency in ADAMTS13 (a disintegrin & metalloprotease with thrombospondin type 1 repeats, member 13), the specific von Willebrand factor (vWf)-cleaving protease.
- BAX 930: Takeda
BAX 930/ TAK755/SHP655 (Shire) is a fully glycosylated recombinant human ADAMTS-13 protein that restores the missing enzyme in a patient’s blood without the risk for complications for human-donor plasma.
The FDA has been granted fast track designation to BAX930 for the therapy of acute episodes of hereditary TTP in patients with a constitutional deficiency of the von Willebrand factor-cleaving (VWF) protease ADAMTS13.
Currently, the drug is in phase III trial, which aims to assess the safety & efficacy of BAX 930 in the prevention & treatment of acute episodes of thrombotic thrombocytopenic purpura in participants with severe congenital deficiency of ADAMTS13.
- Anfibatide: Lee’s Pharmaceutical
Anfibatide (Lee’s Pharmaceutical) is a snake venom-derived protein that acts as a platelet glycoprotein Ib antagonist. It is in Phase II studies being evaluated as adjuvant therapy for plasma exchange in patients with acquired TTP. The drug has received an orphan designation for TTP from the US FDA.
Know More Information @ Thrombotic Thrombocytopenic Purpura Pipeline Drugs
Key Pipeline Therapies along with Companies
- Apadamtase alfa: Takeda
- Anfibatide: Lee’s Pharmaceutical
- HB-adMSCs: Hope Biosciences
By Product Type
- Phase I
- Phase II
- Phase III
By Route of Administration
By Molecule Type
- Small Molecule
- Gene Therapy
- Stem Cell Therapy
By Mechanism of Action
- Protease Inhibitors
- Immune System
By Stage and Route of Administration
By Stage and Product Type
Contact here for more information @ Thrombotic Thrombocytopenic Purpura Pipeline Assessment
Scope of the Report
- Coverage- Global
- Key Market Players- Takeda, Lee’s Pharmaceutical and Hope Biosciences and others
- Key Thrombotic Thrombocytopenic Purpura Pipeline Therapies- Apadamtase alfa, Anfibatide, HB-adMSCs and others
Table of content
|2||Thrombotic Thrombocytopenic Purpura|
|3||Thrombotic Thrombocytopenic Purpura Current Treatment Patterns|
|4||Thrombotic Thrombocytopenic Purpura DelveInsight’s Analytical Perspective|
|6||TTP Late Stage Products (Phase-III)|
|7||TTP mid Stage Products (Phase-II)|
|8||Thrombotic Thrombocytopenic Purpura Early Stage Products (Phase-I)|
|9||Pre-clinical Products and Discovery Stage Products|
|12||TTP Discontinued Products|
|13||TTP Product Profiles|
|14||Thrombotic Thrombocytopenic Purpura Key Companies|
|15||TTP Key Products|
|16||Dormant and Discontinued Products|
|17||Thrombotic Thrombocytopenic Purpura Unmet Needs|
|18||Thrombotic Thrombocytopenic Purpura Future Perspectives|
|19||Thrombotic Thrombocytopenic Purpura Analyst Review|
Know more of what’s covered in the Thrombotic Thrombocytopenic Purpura Pipeline Assessment report
Key Questions Answered in the Thrombotic Thrombocytopenic Purpura report
- What are the current choices for TTP treatment?
- How many key players are developing therapies for the treatment of TTP?
- What is the principal treatment developed by these pharma key players in the sector?
- How many treatments are developed by each company for the treatment of TTP?
- How many TTP emerging therapies are in the early-stage, mid-stage, and late stage of development for the treatment of Thrombotic Thrombocytopenic Purpura?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers & acquisitions, and major licensing activities that will impact the Thrombotic Thrombocytopenic Purpura market?
- Which are the dormant & discontinued products & the causes for the identic?
- What is the unmet necessity for current therapies for the treatment of Thrombotic Thrombocytopenic Purpura?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Thrombotic Thrombocytopenic Purpura therapies?
- What are the clinical studies going on for Thrombotic Thrombocytopenic Purpura and their status?
- What are the consequences of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Thrombotic Thrombocytopenic Purpura?
- How many patents are granted & pending for the emerging therapies for the treatment of Thrombotic Thrombocytopenic Purpura?
Request for a Webex demo @ Thrombotic Thrombocytopenic Purpura Pipeline and get a walk-through of our report
DelveInsight’s Thrombotic Thrombocytopenic Purpura Market Insights, Epidemiology and Market Forecast 2030 report.
DelveInsight’s Thrombotic Thrombocytopenic Purpura – Epidemiology Forecast 2030 report
Thrombotic Thrombocytopenic Purpura Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020″ report
DelveInsight’ s Beta-thalassemia Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight’ s Hemophilia B – Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight’ s Hemophilia – Market Insights, Epidemiology and Market Forecast – 2030 report.
Hypofibrinogenemia Market Insights, Epidemiology, & Market Forecast-2030 report
Visit on our blog section-
- Bleeding Disorders: How Key Companies Are Shaping The Bleeding Disorders Therapeutics Market?
- Hypofibrinogenemia Market: Limited Pipeline Therapies, Abundant Opportunities
- A Royal Disease: Hemophilia
- Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere?
- Overcoming the prevailing unmet needs in Beta-Thalassemia Market
DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.
Shruti Thakur email@example.com +91-9650213330 www.delveinsight.com